Transforming Treatments in Neuropsychiatry
Draig is dedicated to delivering next-generation treatments for neuropsychiatric disorders through the development of highly targeted neuromodulators that redefine the existing treatment paradigm and enable people with neuropsychiatric disorders to live their best life.
Scientific excellence
Driven by the unique expertise of our founders and a highly experienced team with a deep understanding of neuropsychiatric drug development, we are targeting fundamental, clinically validated mechanisms that underlie prevalent and debilitating neuropsychiatric disorders, such as Major Depressive Disorder (MDD).
By developing best-in-class modulators of the primary excitatory and inhibitory neurotransmitters, Glutamate and GABA, we aim to restore synaptic balance and deliver transformative therapeutic benefits for patients.
Best-in-class, clinical stage pipeline
Draig's lead candidate DT-101 is a next-generation AMPA receptor positive allosteric modulator (PAM) aiming to become a transformative treatment option for MDD. DT-101 will enter Phase 2 trials in 2025.
Draig is also advancing highly selective GABAA receptor modulators with strong therapeutic potential for a range of prevalent and underserved neuropsychiatric disorders towards clinical development.
Addressing unmet needs of countless patients
Neuropsychiatric disorders represent a wide range of debilitating conditions, including anxiety disorders, depression (MDD), bipolar disorder, schizophrenia and post-traumatic stress disorder (PTSD). According to the World Health Organization (WHO), 1 in every 8 people in the world is affected, and for a high proportion of these, their condition is poorly managed with currently available treatments.
Draig's lead candidate DT-101 is targeting MDD, a serious mental health condition and a leading cause of disability worldwide.
Latest News
$140 Million to Advance Next-Generation Therapies
Draig Therapeutics Launches with $140 Million to Advance Next-Generation Therapies for Major Neuropsychiatric Disorders
Read Now